The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Annual General Meeting

23 Nov 2016 11:30

RNS Number : 9559P
Diurnal Group PLC
23 November 2016
 

23 November 2016

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Results of Annual General Meeting

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed. All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

 

 

Resolution

For (including discretionary votes)*

Against*

Withheld

Ordinary Resolutions (requires 50% majority)

1. To receive and adopt the Company's audited annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

2. To reappoint Peter Allen as a director.

39,347,209

100%

0

0%

0

3. To reappoint Ian Ardill as a director.

39,347,209

100%

0

0%

0

4. To reappoint John Goddard as a director.

39,347,209

100%

0

0%

0

5. To reappoint Alan Raymond as a director.

39,347,209

100%

0

0%

0

6. To reappoint Richard Ross as a director.

39,347,209

100%

0

0%

0

7. To reappoint Martin Whitaker as a director.

39,347,209

100%

0

0%

0

8. To reappoint Sam Williams as a director.

39,347,209

100%

0

0%

0

9. To receive and approve the directors' remuneration report contained within the annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

10. To reappoint KPMG LLP as auditors of the Company.

39,347,209

100%

0

0%

0

11. To authorise the directors to determine the remuneration of the auditors.

39,347,209

100%

0

0%

0

12. To authorise the directors to allot shares.

39,347,209

100%

0

0%

0

Special Resolutions (requires 75% majority)

13. To authorise the directors to disapply pre-emption rights.

39,347,209

100%

0

0%

0

14. To authorise the Company to make market purchases.

39,347,209

100%

0

0%

0

 

 

* A vote withheld is not a vote in law and is not counted in the calculation of the votes for or against a resolution; the percentage of votes cast therefore excludes withheld votes.

 

On 23 November 2016 there were 52,210,759 Diurnal Group plc ordinary shares in issue. Shareholders are entitled to one vote per share held.

 

The full text of each resolution passed at the Annual General Meeting held earlier today, is set out in the Notice of Annual General Meeting, included in the 2016 Annual Report, which is available on the Company's website www.diurnal.co.uk.

 

 

Please further information, please visit www.diurnal.co.uk or contact:

 

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Ian Ardill, CFO

Numis Securities Ltd

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+ 44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBJBBTMBBTBPF
Date   Source Headline
6th Mar 202011:22 amRNSProposed Placing
5th Mar 20204:41 pmRNSDirectorate Change
28th Feb 20207:30 amEQSHardman & Co Research: Diurnal (DNL): . and more to come (news flow)
25th Feb 20203:06 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 202011:00 amRNSPrice Monitoring Extension
17th Feb 20201:46 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUS FDA Accepts NDA Application for Alkindi
11th Feb 20207:00 amRNSInterim Results
20th Jan 20207:00 amRNSBusiness and trading update
13th Jan 20207:00 amRNSNotice of Interim Results
13th Jan 20207:00 amRNSHolding(s) in Company
10th Jan 20203:45 pmRNSDirector Dealings and Issue of Equity
10th Jan 20203:44 pmRNSIssue of Long-Term Incentive Plan awards
16th Dec 201911:46 amRNSDirector Dealings
16th Dec 20197:00 amRNSChronocort MAA Submitted in Europe
2nd Dec 20192:28 pmRNSShare Option Exercise and Issue of Equity
2nd Dec 20197:01 amRNSHolding(s) in Company
2nd Dec 20197:00 amRNSAlkindi New Drug Application Submitted to US FDA
26th Nov 201910:42 amRNSDirector Dealings and Issue of Equity
26th Nov 20197:15 amEQSHardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
21st Nov 20191:08 pmRNSResults of Annual General Meeting
21st Nov 20197:00 amRNSAGM Statement
20th Nov 20197:00 amRNSSuccessful outcome of testosterone clinical study
8th Nov 20197:00 amRNSVesting of LTIP awards
5th Nov 20197:30 amEQSHardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
21st Oct 20196:23 pmRNSIssue of Equity
21st Oct 20191:09 pmRNSDirector Dealings
8th Oct 201911:26 amRNSPosting of Annual Report and AGM Notice
24th Sep 20197:00 amRNSResults for the year ended 30 June 2019
7th Aug 201911:04 amRNSDirector Dealings
5th Aug 201912:27 pmRNSDirector/PDMR Shareholding
26th Jul 20194:32 pmRNSHolding(s) in Company
8th Jul 20192:07 pmRNSDirector Dealings and Issue of Equity
3rd Jul 20197:00 amRNSMarket Authorisation Application in Australia
26th Jun 20193:57 pmRNSHolding(s) in Company
24th Jun 20199:39 amRNSDirector Dealings
21st Jun 20193:40 pmRNSHolding(s) in Company
21st Jun 20193:35 pmRNSHolding(s) in Company - Replacement
21st Jun 201910:18 amRNSChange of Auditor
19th Jun 20194:08 pmRNSHolding(s) in Company
18th Jun 20195:30 pmRNSHolding(s) in Company
18th Jun 20192:03 pmRNSDirector Dealings
17th Jun 201912:05 pmRNSDirector Dealings
14th Jun 201912:39 pmRNSResult of General Meeting and Issue of Equity
14th Jun 20197:00 amRNSResult of Open Offer
28th May 20197:00 amRNSPlacing, Open Offer and Notice of General Meeting
9th May 20197:00 amRNSIntent to Submit for MAA tendered to the EMA
2nd May 20193:29 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.